HEART UK conducts campaigning activities in Scotland, working with Key Opinion Leaders to ensure that cardiovascular disease is recognised as a key health priority in Scotland.
Examples of recent and previous work are outlined below.
Saving Scottish Lives, Saving Scotland's Money: Report on the advantages of implementing cascade screening for familial hypercholesterolaemia (FH) in Scotland
On 30 April 2013, HEART UK launched this new report in the Scottish Parliament on the inherited form of high cholesterol, FH, a genetic condition that may affects as many as one in 250 people. People with FH have high concentrations of cholesterol in their blood and are at increased risk of developing coronary heart disease from a young age. This report focuses on Scotland, and evaluates the experiences of patients diagnosed with FH, as well as considering economic data on the associated health and social care costs. The report includes recommendations for the Scottish Government's consideration to develop a programme to better meet the needs of the 20,000 Scots affected by the condition. Download the report here.
Heart Hotspots Scotland
Following the successful launch of Heart Hotspots in England at the HEART UK Conference, HEART UK was pleased to partner with MSD for the September 2011 launch of Heart Hotspots Scotland in Edinburgh. The Heart Hotspots campaign aims to raise awareness of the inequalities in coronary heart disease (CHD) and empower patients to take an active role in looking after their heart health. The Heart Hotspots Scotland data highlights the East/West divide between rates of CHD in Scotland. Eminent speakers addressed the reception, including Scotland’s Deputy First Minister Nicola Sturgeon. The event attracted good cross-party MSP representation, and enjoyed excellent media coverage across Scotland.
The Heart Hotspots website is available at www.heart-hotspots.co.uk
‘Dragon’s Den’ event
In December 2010, at a ‘Dragon’s Den’ style event aimed at Members of the Scottish Parliament (MSPs), Dr Bill Simpson presented HEART UK’s case for increasing efforts to diagnose and treat cases of familial hypercholesterolaemia (FH) in Scotland. This event helped to bolster the profile of FH in Scotland, including near complete Scottish media coverage about FH.
Scotland SIGN 97 guideline review
HEART UK presented the findings of its review of the implementation of SIGN 97 guidance in respect of cardiovascular disease in Scotland at an event in the Scottish Parliament in December 2008. This review was supported by a partnership of the ABPI Scottish Cardio Vascular Industry Group together with AstraZeneca, Bristol Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Pfizer, Sanofi-Aventis, Schering-Plough, Takeda.